$1.32M in average volume shows that Avidity Biosciences Inc (RNA) is heading in the right direction

On Tuesday, Avidity Biosciences Inc (NASDAQ: RNA) was -4.49% drop from the session before settling in for the closing price of $30.53. A 52-week range for RNA has been $14.10 – $56.00.

Healthcare Sector giant saw their annual sales surged by 58.16% over the last five years. When this article was written, the company’s average yearly earnings per share was at 3.21%. With a float of $110.23 million, this company’s outstanding shares have now reached $118.90 million.

The firm has a total of 253 workers. Let’s measure their productivity. In terms of profitability, gross margin is 80.79%, operating margin of -3209.35%, and the pretax margin is -2772.45%.

Avidity Biosciences Inc (RNA) Insider Activity

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Avidity Biosciences Inc stocks. The insider ownership of Avidity Biosciences Inc is 7.61%, while institutional ownership is 104.64%. The most recent insider transaction that took place on Feb 03 ’25, was worth 188,918. In this transaction Chief Program Officer of this company sold 5,875 shares at a rate of $32.16, taking the stock ownership to the 50,554 shares. Before that another transaction happened on Feb 03 ’25, when Company’s Officer proposed sale 17,625 for $32.93, making the entire transaction worth $580,391.

Avidity Biosciences Inc (RNA) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.77 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 3.21% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.10% during the next five years compared to -57.60% drop over the previous five years of trading.

Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators

You can see what Avidity Biosciences Inc (RNA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 17.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 343.78.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.90, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -3.36 in one year’s time.

Technical Analysis of Avidity Biosciences Inc (RNA)

Analysing the last 5-days average volume posted by the [Avidity Biosciences Inc, RNA], we can find that recorded value of 1.3 million was lower than the volume posted last year of 1.35 million. As of the previous 9 days, the stock’s Stochastic %D was 14.23%. Additionally, its Average True Range was 1.87.

During the past 100 days, Avidity Biosciences Inc’s (RNA) raw stochastic average was set at 8.27%, which indicates a significant increase from 6.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.71% in the past 14 days, which was lower than the 60.93% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $31.42, while its 200-day Moving Average is $38.57. Now, the first resistance to watch is $30.65. This is followed by the second major resistance level at $32.15. The third major resistance level sits at $33.11. If the price goes on to break the first support level at $28.19, it is likely to go to the next support level at $27.23. Should the price break the second support level, the third support level stands at $25.73.

Avidity Biosciences Inc (NASDAQ: RNA) Key Stats

There are 119,309K outstanding shares of the company, which has a market capitalization of 3.48 billion. As of now, sales total 9,560 K while income totals -212,220 K. Its latest quarter income was 2,340 K while its last quarter net income were -80,400 K.